在严重喘中进行生物疗法前后肺功能长期纵向分析
International archives of allergy and immunology
|May 15, 2025
概括
生物药物可以改善2型炎症严重喘患者的肺功能. 这些治疗有助于防止逐渐下降,特别是在那些具有先前存在的肺功能损失或高T2生物标志物的患者中.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 生物药物对于治疗2型 (T2) 炎症的严重喘至关重要.
- 虽然对症状和恶化是有效的,但它们对肺功能的长期影响,特别是每秒强迫呼气量 (FEV1) 的理解较少.
研究的目的:
- 在开始生物疗法之前和之后,分析严重喘患者FEV1的纵向变化.
- 评估生物制剂在长期随访期间对肺功能的长期影响.
主要方法:
- 包括至少有三次精神测量测量和至少两年随访的患者.
- 主要结果:FEV1 (ΔFEV1) 的年度变化.
- 二次结果:基于 ΔFEV1 的改善/恶化,生物类型和临床缓解状态的比较.
主要成果:
- 总体 ΔFEV1 显著改善了后生物学启动 (p < 0.001).
- 在先前FEV1下降的患者中观察到更大的FEV1改善,特别是使用抗IL-5或抗IL-4受体生物药物.
- 增加的T2生物标志物 (FeNO,PBE) 与更大的FEV1改善相关.
结论:
- 生物药物显示出预防严重喘肺功能逐渐下降的潜力.
- 在治疗前肺功能显著下降或T2生物标志物升高的患者可能受益最多.
- 需要进一步的研究来比较不同生物制剂的疗效.
更多相关视频
07:38A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice
Published on: April 13, 2018
11.4K
00:07Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
Published on: August 24, 2019
9.6K
相关概念视频
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
2.5K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
2.5K
Pulmonary Function Tests
277
Pulmonary Function Tests (PFTs)
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
277
Lung Capacity
48.2K
The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
48.2K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K
COPD: Management Using Bronchodilators and Corticosteroids
148
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
148
Chronic Obstructive Pulmonary Disease-I: Introduction
2.7K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.7K
